A nationwide Danish study found that oral menopausal hormone therapy is associated with elevated risk of venous thromboembolism regardless of dose, while high-dose oral forms also increased stroke and heart attack risk. Transdermal treatments showed no overall increase in thrombotic risk.
The Pentagon issued new guidance requiring testosterone deficiency screening for male active-duty and reserve service members over age 30, after temporarily rescinding previous guidance earlier in September. Officials said rules for female service members will be released later.
Multiple studies released this week show hormone therapy during menopause may reduce heart disease risk and improve mood symptoms, while supplements marketed for menopause lack evidence and contain inconsistent doses. The research comes amid growing attention to the economic costs of menopause symptoms for women.
The Pentagon has temporarily rescinded recently published clinical guidance that would have required mandatory testosterone deficiency screening for male service members aged 30 and older. The policy was announced by Defense Secretary Pete Hegseth over the summer but the guidance issued Wednesday was quickly pulled back.
A major study published in The Lancet analyzing 2.5 million U.S. women found that those with polyendocrine metabolic ovarian syndrome (PMOS, formerly PCOS) have four times the risk of cardiovascular disease, including heart attacks and strokes, compared to women without the condition.
Defense Secretary Pete Hegseth announced mandatory annual testosterone deficiency screenings for US service members 30 years and older as part of their physical exams, an initiative he said was aimed at improving warfighter readiness.
Healthcare providers and patients across the United States are reporting intermittent shortages of oral progesterone, a hormone widely used in fertility and menopause treatments. The supply strain reflects growing demand for hormone replacement therapy.
A large UK trial published in the New England Journal of Medicine found that women's hormone replacement therapy patches can treat prostate cancer just as effectively as standard hormone injections but with fewer severe side effects.
Cornell researchers have taken a significant step toward developing a safe, reversible, long-acting and 100% effective nonhormonal male contraceptive, with proof-of-concept results representing progress toward what's considered the 'holy grail' of male contraception.
